Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore

Inclusion Criteria :

• Aged from 2 to 45 years on the day of inclusion.
• Subject in good health, based on medical history and physical examination.
• Provision of informed consent form (and assent form for subjects aged 6 to 12 years) signed by the subject and by the parent(s) or another legally acceptable representative for subjects aged less than 21 years.
• Subject and parent(s)/legally acceptable representative able to attend all scheduled visits and comply with all trial procedures.
• For a woman of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks before the first vaccination until 4 weeks after the last vaccination.

Exclusion Criteria :

• Febrile illness (temperature ≥ 37.5°C) or moderate or severe acute illness/infection on the day of the first vaccination, according to Investigator judgment.
• For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test on the day of inclusion.
• Breast-feeding woman.
• Known systemic hypersensitivity to any of the components of the trial vaccines (especially egg proteins or neomycin) or history of a life-threatening reaction to the trial vaccines or to a vaccine containing any of the same substances.
• Personal or family history of thymic pathology or myasthenia.
• Previous hepatitis A vaccination (for children only).
• Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the past 6 months, or long-term systemic corticosteroid therapy.
• Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.
• Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of immune response.
• Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination.
• Planned participation in another clinical trial during the 18 coming months.
• Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.
• Planned receipt of any vaccine in the 4 weeks following the first trial vaccination.
• Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
• Current or past alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures.
• Subject who plans to move to another country within the 18 coming months.